Extent Of Tumor Hypoxia Research Articles

Hypoxia-Triggered Self-Assembly of Ultrasmall Iron Oxide Nanoparticles to Amplify the Imaging Signal of a Tumor.

Hypoxia is a common phenomenon among most solid tumors that significantly influences tumor response toward chemo- and radiotherapy. Understanding the distribution and extent of tumor hypoxia in patients will be very important to provide personalized therapies in the clinic. Without sufficient vessels, however, traditional contrast agents for clinical imaging techniques will have difficulty in accumulating in the hypoxic region of solid tumors, thus challenging the detection of hypoxia in vivo. To overcome this problem, herein we develop a novel hypoxia imaging probe, consisting of a hypoxia-triggered self-assembling ultrasmall iron oxide (UIO) nanoparticle and assembly-responding fluorescence dyes (NBD), to provide dual-mode imaging in vivo. In this strategy, we have employed nitroimidazole derivatives as the hypoxia-sensitive moiety to construct intermolecular cross-linking of UIO nanoparticles under hypoxia, which irreversibly form larger nanoparticle assemblies. The hypoxia-triggered performance of UIO self-assembly not only amplifies its T2-weighted MRI signal but also promotes the fluorescence intensity of NBD through its emerging hydrophobic environment incorporated into self-assemblies. In vivo results further confirm that our hypoxic imaging probe can display a prompt MRI signal for the tumor interior region, and its signal enhancement performs a long-term effective feature and gradually reaches 3.69 times amplification. Simultaneously, this probe also exhibits obvious green fluorescence in the hypoxic region of tumor sections. Accordingly, we also have developed a MRI difference value method to visualize the 3D distribution and describe the extent of the hypoxic tumor region within the whole bodies of mice. Due to its notable efficiency of penetration and accumulation inside a hypoxic tumor, our hypoxia imaging probe could also be considered as a potential candidate as a versatile platform for hypoxia-targeted drug delivery, and meanwhile its hypoxia-related therapeutic efficacy can be monitored.

DCE-MRI of Tumor Hypoxia and Hypoxia-Associated Aggressiveness.

Tumor hypoxia is associated with resistance to treatment, aggressive growth, metastatic dissemination, and poor clinical outcome in many cancer types. The potential of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to assess the extent of hypoxia in tumors has been investigated in several studies in our laboratory. Cervical carcinoma, melanoma, and pancreatic ductal adenocarcinoma (PDAC) xenografts have been used as models of human cancer, and the transfer rate constant (Ktrans) and the extravascular extracellular volume fraction (ve) have been derived from DCE-MRI data by using Tofts standard pharmacokinetic model and a population-based arterial input function. Ktrans was found to reflect naturally occurring and treatment-induced hypoxia when hypoxia was caused by low blood perfusion, radiation responsiveness when radiation resistance was due to hypoxia, and metastatic potential when metastasis was hypoxia-induced. Ktrans was also associated with outcome for patients with locally-advanced cervical carcinoma treated with cisplatin-based chemoradiotherapy. Together, the studies imply that DCE-MRI can provide valuable information on the hypoxic status of cervical carcinoma, melanoma, and PDAC. In this communication, we review and discuss the studies and provide some recommendations as to how DCE-MRI data can be analyzed and interpreted to assess tumor hypoxia.

Volume effects in the TCP for hypoxic and oxygenated tumors.

Clinical studies in radiation therapy with conventional fractionation show a reduction in the tumor control probability (TCP) with an increase in the total and hypoxic tumor volumes. The main objective of this article is to derive an analytical relationship between the TCP and the hypoxic and total tumor volumes. This relationship is applied to clinical data on the TCP reduction with increasing total tumor volume and, also, dose escalation to target tumor hypoxia. The TCP equation derived from the Poisson probability distribution predicts that both (a) an increase in the number of tumor clonogens and (b) an increase in the average cell surviving fraction are the factors contributing to the loss of local control. Using asymptotic mathematical properties of the TCP formula and the linear quadratic (LQ) cell survival model with two levels of hypoxic and oxygenated cells, we separated the TCP dependence on the total and hypoxic tumor volumes. The predicted trends in the local control as a function of total and hypoxic tumor volumes were evaluated in radiotherapy model problems with conventional dose fractionation for head and neck and non-small cell lung cancers. Tumor-specific parameters in the LQ model and the density of clonogens in the TCP model were taken from published data on predictive assays and the plating efficiency measurements, respectively. Our simulations show that, at the dose levels used in conventional radiation therapy for head and neck and non-small cell lung cancers, the TCP dependence on the total tumor volume is negligible for completely oxygenated tumors. However, the presented results demonstrate that tumor hypoxia introduces a significant volume effect into estimates of the TCP. The extent of tumor hypoxia is a plausible mechanism to explain the TCP reduction with increasing total tumor volume observed in clinical studies. To achieve the same level of tumor control in a hypoxic tumor region relative to well oxygenated tumor regions, the delivered dose should, in principle, be escalated by a factor equal to the oxygen enhancement ratio (OER). The theoretically required hypoxia-targeted dose escalation could be as large as 100% because it has been estimated that hypoxic tumor regions may have an OER=2 for conventional fractionation. However, our results indicate that clinically acceptable values of the TCP would require much lower hypoxia-targeted dose escalation (<50%) when the effects of total and hypoxic tumor volumes are taken into account. The reported studies and models suggest that the effect of total tumor volume on the TCP is negligible for oxygenated head and neck and non-small cell lung tumors treated with conventional fractionation. According to our simulations, the volume effects in the TCP observed in clinical studies are defined primarily by the hypoxic volume. This information can be useful for the analysis of treatment outcomes and the dose escalation to target tumor hypoxia.

Localized Hypoxia Results in Spatially Heterogeneous Metabolic Signatures in Breast Tumor Models

Tumor hypoxia triggers signaling cascades that significantly affect biologic outcomes such as resistance to radiotherapy and chemotherapy in breast cancer. Hypoxic regions in solid tumor are spatially heterogeneous. Therefore, delineating the origin and extent of hypoxia in tumors is critical. In this study, we have investigated the effect of hypoxia on different metabolic pathways, such as lipid and choline metabolism, in a human breast cancer model. Human MDA-MB-231 breast cancer cells and tumors, which were genetically engineered to express red fluorescent tdTomato protein under hypoxic conditions, were used to investigate hypoxia. Our data were obtained with a novel three-dimensional multimodal molecular imaging platform that combines magnetic resonance (MR) imaging, MR spectroscopic imaging (MRSI), and optical imaging of hypoxia and necrosis. A higher concentration of noninvasively detected total choline-containing metabolites (tCho) and lipid CH3 localized in the tdTomato-fluorescing hypoxic regions indicated that hypoxia can upregulate tCho and lipid CH3 levels in this breast tumor model. The increase in tCho under hypoxia was primarily due to elevated phosphocholine levels as shown by in vitro MR spectroscopy. Elevated lipid CH3 levels detected under hypoxia were caused by an increase in mobile MR-detectable lipid droplets, as demonstrated by Nile Red staining. Our findings demonstrate that noninvasive MRSI can help delineate hypoxic regions in solid tumors by means of detecting the metabolic outcome of tumor hypoxia, which is characterized by elevated tCho and lipid CH3.

ACRIN 6684 assessment of tumor hypoxia in glioblastoma using 18F-fluoromisonidazole with PET and MRI.

TPS10635 Background: Glioblastoma (GBM) is an aggressive type of primary malignant brain tumor and despite treatment with surgery, radiation, and temozolomide (TMZ) chemotherapy, median overall survival (OS) remains poor. A pathologic hallmark of GBM is tumor necrosis, a suspected result from endogenous tumor hypoxia. Angiogenesis is stimulated by hypoxia-driven signaling cascades and is required for tumor proliferation. The inefficient blood supply of these hypoxic tumors also limits the efficacy of chemotherapy and radiotherapy. Surviving hypoxic tumor cells may be selected out and proliferate as a more aggressive tumor subtype, therefore hindering OS. 18F-Fluoromisonidazole (FMISO) is a PET radiotracer whose uptake in hypoxic tissues can be measured radiographically. The degree of tumor hypoxia has been negatively associated with time to tumor progression and survival (Spence et al, 2008). Knowledge of the degree/distribution of tumor hypoxia by PET uptake and perfusion MRI parameters may provide prognostic information and help guide therapy for patients with GBM. Methods: In this phase II prospective single arm multi-institution study, patients will undergo baseline FMISO PET and MR imaging two weeks prior to chemoradiotherapy (CRT). A subset of patients will receive a second FMISO PET one week prior to CRT to assess reproducibility. Clinical outcomes of OS and 6-month progression-free survival (PFS-6) will be correlated to PET and MRI parameters. Eligibility: Pathologically confirmed GBM with residual tumor after surgery (including T2/FLAIR hyperintensity consistent with tumor) scheduled to receive standard fractionated radiation therapy and temozolomide alone or with an anti-VEGF agent or PARP inhibitor. Current enrollment: 22 patients of 50 sample size Contact information: Please contact the PI, Elizabeth R. Gerstner, MD ( egerstner@partners.org ) for additional information. Significance: With a better understanding of the extent of tumor hypoxia and changes in hypoxia levels from treatment, more effective therapies could be developed to inhibit GBM growth, target hypoxic areas and individualize patient care.

Hypoxia upregulates Hsp90α expression via STAT5b in cancer cells

Hsp90α is a molecular chaperone protein involved in the structural maturation of oncogenic signaling proteins. Hsp90 was recently identified as an anticancer target; various studies are ongoing to find ways for managing cancer through Hsp90α. However, this approach is limited by reported side-effects. Hypoxia is a hallmark of solid tumors, including those of breast cancer and the extent of tumor hypoxia is associated with resistance to treatment and poor prognosis. One of the major signaling pathways in cancer cells, the Jak2/STAT5b pathway, has been found to be closely correlated with hypoxia. The objective of this study was to investigate the role of Jak2/STAT5b in the regulation of Hsp90α expression so that Hsp90α targeting can be achieved indirectly by modulating the Jak2/STAT5b pathway. We examined the role of the Jak2/STAT5b pathway in the expression of Hsp90α under hypoxic conditions by immunoblotting, reporter gene assays, EMSA and RNA interference analysis. With the help of in vivo models, we also analyzed the expression of Hsp90α in different parts of solid tumor tissues. We found a close association between hypoxic stress and Hsp90α expression. We also determined that STAT5b regulates the expression of Hsp90α during hypoxic stimulation. Under hypoxic conditions the expression of Hsp90α and STAT5b were proportional. siRNA analysis and nucleotide analysis showed that the promoter of Hsp90α has a STAT5b binding domain. Our work confirmed that STAT5b is one of the transcription factors that regulate Hsp90α. We, therefore, concluded that under hypoxic conditions, the Jak2/STAT5b pathway regulates Hsp90α expression and it could serve as a promising target for the treatment of solid tumors.

Abstract LB-242: Mammalian orthoreovirus downregulates HIF-1α in hypoxic prostate tumor cells via RACK1-mediated proteasomal degradation and translational inhibition

Abstract The purpose of our study was to investigate the oncolytic properties of mammalian orthoreovirus (MRV) on hypoxic prostate tumor cells. Outgrowth from the blood supply and abnormal vascularization leads to poor oxygenation, or hypoxia, within tumors. Hypoxia results in modification of many genes, largely through the activation of the hypoxia inducible factor alpha (HIF-1α) transcription factor. Hypoxia-induced changes lead to tumor propagation through the selection of mutant cells that are capable of clonal expansion and metastases. For these reasons, the extent of hypoxia in tumors correlates with cancer progression, therapy resistance and mortality. MRV is a clinically benign member of the family Reoviridae and is a potent oncolytic agent that replicates in cell lines derived from common tumors. MRV therapy has been tested in numerous clinical trials, and is a safe and effective treatment for many tumor types. We investigated MRV replication in hypoxic prostate tumor cells and found that the virus exhibited robust replication in cells grown in hypoxic conditions. We measured cell cytotoxicity and apoptosis and found that the virus induces cell death by apoptosis in these cells. We additionally examined HIF-1α levels in MRV infected hypoxic prostate tumor cells and found that there are substantially diminished levels of HIF-1α protein in these cells. MRV-induced loss of HIF-1α was reversed when proteasome inhibitors were added at early times to infected hypoxic cells, suggesting that infection results in increased degradation of the HIF-1α protein. However, HIF-1α protein did not accumulate when proteasome inhibitors were added at later times in infection. There were no significant changes in HIF-1α mRNA levels; suggesting MRV also induces downregulation of HIF-1α protein through a second pathway involving virus-induced translational inhibition. siRNA knockdown of the receptor for activated kinase C (RACK1) protein rescued HIF-1α protein expression in MRV infected cells, suggesting that the proteasome-dependent degradation of HIF-1α in MRV infected cells occurs through a RACK1-mediated pathway. Release of RACK1 from cellular stress granule sequestration in infected hypoxic prostate tumor cells was also demonstrated providing a link between virus-induced cellular dysregulation and HIF-1α degradation. Based on these data, we conclude that MRV induces apoptotic cell death and downregulation of the master regulator of hypoxia, HIF-1α, via RACK1-dependent, proteasome-mediated degradation and virus induced translational shutoff in hypoxic prostate tumor cells. This study demonstrates the potential value of inclusion of MRV in clinical treatment modalities to target hypoxic prostate tumor cells at all stages of prostate cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-242. doi:1538-7445.AM2012-LB-242

Antiangiogenic and Radiation Therapy

To assess early treatment effects on computed tomography (CT) perfusion parameters after antiangiogenic and radiation therapy in subcutaneously implanted, human colon cancer xenografts in mice and to correlate in vivo CT perfusion parameters with ex vivo assays of tumor vascularity and hypoxia. Dynamic contrast-enhanced CT (perfusion CT, 129 mAs, 80 kV, 12 slices × 2.4 mm; 150 μL iodinated contrast agent injected at a rate of 1 mL/min intravenously) was performed in 100 subcutaneous human colon cancer xenografts on baseline day 0. Mice in group 1 (n=32) received a single dose of the antiangiogenic agent bevacizumab (10 mg/kg body weight), mice in group 2 (n=32) underwent a single radiation treatment (12 Gy), and mice in group 3 (n=32) remained untreated. On days 1, 3, 5, and 7 after treatment, 8 mice from each group underwent a second CT perfusion scan, respectively, after which tumors were excised for ex vivo analysis. Four mice were killed after baseline scanning on day 0 for ex vivo analysis. Blood flow (BF), blood volume (BV), and flow extraction product were calculated using the left ventricle as an arterial input function. Correlation of in vivo CT perfusion parameters with ex vivo microvessel density and extent of tumor hypoxia were assessed by immunofluorescence. Reproducibility of CT perfusion parameter measurements was calculated in an additional 8 tumor-bearing mice scanned twice within 5 hours with the same CT perfusion imaging protocol. The intraclass correlation coefficients for BF, BV, and flow extraction product from repeated CT perfusion scans were 0.93 (95% confidence interval: 0.78, 0.97), 0.88 (0.66, 0.95), and 0.88 (0.56, 0.95), respectively. Changes in perfusion parameters and tumor volumes over time were different between treatments. After bevacizumab treatment, all 3 perfusion parameters significantly decreased from day 1 (P ≤ 0.006) and remained significantly decreased until day 7 (P ≤ 0.008); tumor volume increased significantly only on day 7 (P=0.04). After radiation treatment, all 3 perfusion parameters decreased significantly on day 1 (P < 0.001); BF and flow extraction product increased again on day 3 and 5, although without reaching statistically significant difference; and tumor volumes did not change significantly at all time points (P ≥ 0.3). In the control group, all 3 perfusion parameters did not change significantly, whereas tumor volume increased significantly at all the time points, compared with baseline (P ≤ 0.04). Ex vivo immunofluorescent staining showed good correlation between all 3 perfusion parameters and microvessel density (ρ=0.71, 0.66, and 0.69 for BF, BV, and flow extraction product, respectively; P < 0.001). There was a trend toward negative correlation between extent of hypoxia and all 3 perfusion parameters (ρ=-0.53, -0.47, and -0.40 for BF, BV, and flow extraction product, respectively; P ≥ 0.05). CT perfusion allows a reproducible, noninvasive assessment of tumor vascularity in human colon cancer xenografts in mice. After antiangiogenic and radiation therapy, BF, BV, and flow extraction product significantly decrease and change faster than the tumor volume.

Assessment of hypoxia and radiation response in intramuscular experimental tumors by dynamic contrast-enhanced magnetic resonance imaging

Background and purposeStudies of intradermal melanoma xenografts have suggested that dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may be a useful method for assessing the extent of hypoxia in tumors. Because the microvascular network of tumors is influenced significantly by the site of growth, we challenged this possibility in the present work by studying relationships between DCE-MRI-derived parameters and hypoxia in intramuscular melanoma xenografts. Materials and methodsIntramuscular R-18, U-25, and V-27 tumors were subjected to DCE-MRI and measurement of the fraction of radiobiologically hypoxic cells (HFRad). Parametric images of Ktrans and ve were produced by pharmacokinetic analysis, and Ktrans and ve were related to HFRad in individual tumors. ResultsKtrans decreased with increasing HFRad. The correlations between Ktrans and HFRad were similar for the three tumor lines and were highly significant (P<0.00001). There was no correlation between ve and HFRad. However, ve decreased significantly with increasing cell survival after single dose irradiation. ConclusionIntramuscular melanoma xenografts show similar inverse correlations between Ktrans and HFRad as intradermal tumors, which support the current clinical attempts to establish DCE-MRI as a method for detecting hypoxia and defining therapeutic targets in tumors.

Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro

Hypoxia is a hallmark of solid tumors, including breast cancer, and the extent of tumor hypoxia is associated with treatment resistance and poor prognosis. Considering the limited treatment of hypoxic tumor cells and hence a poor prognosis of breast cancer, the investigation of natural products as potential chemopreventive anti-angiogenic agents is of paramount interest. Rhein (4,5-dihydroxyanthraquinone-2-carboxylic acid), the primary anthraquinone in the roots of Cassia alata L., is a naturally occurring quinone which exhibits a variety of biologic activities including anti-cancer activity. However, the effect of rhein on endothelial or cancer cells under hypoxic conditions has never been delineated. Therefore, the aim of this study was to investigate whether rhein inhibits angiogenesis and the viability of hormone-dependent (MCF-7) or -independent (MDA-MB-435s) breast cancer cells in vitro under normoxic or hypoxic conditions. Rhein inhibited vascular endothelial growth factor (VEGF 165)-stimulated human umbilical vein endothelial cell (HUVEC) tube formation, proliferation and migration under normoxic and hypoxic conditions. In addition, rhein inhibited in vitro angiogenesis by suppressing the activation of phosphatidylinositol 3-kinase (PI3K), phosphorylated-AKT (p-AKT) and phosphorylated extracellular signal-regulated kinase (p-ERK) but showed no inhibitory effects on total AKT or ERK. Rhein dose-dependently inhibited the viability of MCF-7 and MDA-MB-435s breast cancer cells under normoxic or hypoxic conditions, and inhibited cell cycle in both cell lines. Furthermore, Western blotting demonstrated that rhein inhibited heat shock protein 90alpha (Hsp90α) activity to induce degradation of Hsp90 client proteins including nuclear factor-kappa B (NF-κB), COX-2, and HER-2. Rhein also inhibited the expression of hypoxia-inducible factor-1 alpha (HIF-1α), vascular endothelial growth factor (VEGF 165), epidermal growth factor (EGF), and the phosphorylation of inhibitor of NF-κB (I-κB) under normoxic or hypoxic conditions. Taken together, these data indicate that rhein is a promising anti-angiogenic compound for breast cancer cell viability and growth. Therefore, further studies including in vivo and pre-clinical need to be performed.

Quantitative assessment of hypoxia in melanoma xenografts by dynamic contrast-enhanced magnetic resonance imaging: Intradermal versus intramuscular tumors

Background and purpose Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has been suggested to be a useful method for assessing the extent of hypoxia in tumors. In this study, we investigated whether differences in hypoxic fraction between tumors caused by the site of growth can be detected by DCE-MRI. Materials and methods Intradermal and intramuscular A-07 tumors were subjected to DCE-MRI, histological analysis of microvascular characteristics, and measurement of hypoxic cell fractions using a radiobiological assay and a pimonidazole-based immunohistochemical assay. Parametric images of E· F (blood perfusion) and v e (extracellular volume fraction) were produced by pharmacokinetic analysis of the DCE-MRI series. Results The intramuscular tumors had 3–4-fold higher hypoxic fractions than the intradermal tumors, owing to a lower microvascular density. This difference in extent of hypoxia was not detectable in the parametric MR images. Most likely, larger vessel diameters compensated for the lower vessel density in the intramuscular tumors, resulting in E· F images that were similar to those of the intradermal tumors. Conclusion Quantitative assessment of hypoxic fractions from parametric MR images may require tumor site-specific translational criteria.

Assessment of Fraction of Hypoxic Cells in Human Tumor Xenografts with Necrotic Regions by Dynamic Contrast-Enhanced MRI

The potential usefulness of gadopentetate dimeglumine (Gd-DTPA)-based dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for assessing hypoxia in tumors with significant necrosis was investigated. Small (100-350 mm(3)) and large (500-1000 mm(3)) D-12 and U-25 tumors were subjected to DCE-MRI, measurement of the fraction of necrotic tissue, and measurement of the fraction of radiobiologically hypoxic cells. Images of E.F (E is the initial extraction fraction of Gd-DTPA and F is perfusion) and lambda (lambda is proportional to extracellular volume fraction) were produced by subjecting the DCE-MRI data to Kety analysis. Necrotic tissue could be identified in lambda images but not in E.F images of the tumors. Most voxels in viable tissue showed lambda values of 0.15-0.70, whereas the lambda values of most voxels in necrotic tissue were either <0.15 or >0.70. The E.F and lambda frequency distributions of the viable tissue, but not the E.F and lambda frequency distributions of the whole tissue, were consistent with the observation that the four groups of tumors showed similar fractions of radiobiologically hypoxic cells. E.F and lambda images may thus provide useful information on the extent of hypoxia in tumors provided that voxels in necrotic tumor regions are identified and excluded from the images.

Hypoxia in head and neck cancer: How much, how important?

Hypoxia develops in tumors because of a less ordered, often chaotic, and leaky vascular supply compared with that in normal tissues. In preclinical models, hypoxia has been shown to be associated with treatment resistance and increased malignant potential. In the clinic, several reports show the presence and extent of tumor hypoxia as a negative prognostic indicator. This article reviews the biology and importance of hypoxia in head and neck cancer. A review of literature was carried out and combined with our own experience on hypoxia measurements using exogenous and endogenous markers. Hypoxia can increase resistance to radiation and cytotoxic drugs and lead to malignant progression, affecting all treatment modalities, including surgery. Hypoxia measurements using electrodes, exogenous bioreductive markers, or endogenous markers show the presence of hypoxia in most head and neck cancers, and correlations with outcome, although limited, consistently indicate hypoxia as an important negative factor. Each hypoxia measurement method has disadvantages, and no "gold standard" yet exists. Distinctions among chronic, acute, and intermediate hypoxia need to be made, because their biology and relevance to treatment resistance differ. Reliable methods for measuring these different forms in the clinic are still lacking. Several methods to overcome hypoxia have been tested clinically, with radiosensitizers (nimorazole), hypoxic cytotoxins (tirapazamine), and carbogen showing some success. New treatments such as hypoxia-mediated gene therapy await proper clinical testing. The hypoxia problem in head and neck cancer needs to be addressed if improvements in current treatments are to be made. Increased knowledge of the molecular biology of intermediate, severe, and intermittent hypoxia is needed to assess their relevance and indicate strategies for overcoming their negative influence.

Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors

Background and purposeThe present studies were undertaken to determine whether 19F MRS could be used to quantify the binding of the pentafluorinated derivative of etanidazole (EF5) in hypoxic cells of solid tumors. Materials and methodsA 4.7T imaging magnet was used for the in situ and in vitro evaluation of EF5 signals. In order to develop a better understanding of these NMR measurements the characteristics of parent, reduced unbound, and reduced bound EF5 signals were examined in vitro using a 12T spectrometer. ResultsIn situ data acquired using a 4.7T imaging magnet, showed retention of EF5 signals in KHT sarcomas that was absent in muscles for 6h after EF5 injection. In vitro studies showed no difference in the NMR detectable signal of parent and reduced unbound EF5. T2 values determined using parent EF5 samples revealed a T2 time of 675ms. In contrast, EF5 bound to KHT tumor cells gave rise to signals of low intensity, broad line widths, and T2 relaxation times of less than 30ms. When the same samples were analyzed using the 4.7T imaging magnet, the CF3 and CF2 fluorine peaks were readily identifiable in the parent EF5 sample but no fluorine signal could be detected from EF5 bound to KHT tumor cells. ConclusionThe inability to resolve bound EF5 metabolites even at high field strengths (12T), coupled with the short T2 relaxation times of the bound EF5, and the limits of detection of the in situ applied imaging magnet (4.7T), meant that hypoxic cells could not be quantified in tumors using the 19F MRS technique. In situ 19F MRS measurements of EF5 signals (parent/reduced unbound) may reflect conditions of tumor physiology and thus indicate the extent of tumor hypoxia but they are not capable of resolving the cellular oxygenation status of the tumor cells.

In vivo measurements of tumor oxygenation and metabolism using electron paramagnetic resonance spectroscopy/imaging

Purpose/Objective: Oxygen is critical for radiation response in tumors. Presence of hypoxia in tumors is known to cause radiation treatment failures. Knowledge of the qualitative and quantitative extent of hypoxia in tumors will lead to improvement in radiation treatment techniques. We have studied the effectiveness of utilizing noninvasive electron paramagnetic resonance (EPR) oximetry for in vivo measurement of oxygen levels in normal tissues and in tumors, at 37C and at 24C. Stable free radical probes such as the nitroxides 3-CP and Tempol (TPL) and phthalocyanine (LiPc), which undergo paramagnetic line-broadening in the presence of molecular oxygen, were used. The LiPc is known to be nontoxic and stable in tissues and its EPR line-width shows sensitivity to oxygen over a wide range of concentrations. The studies were performed in RIF-1 tumors in C3H mice. For comparison, the oxygen levels in the muscle of non-tumor bearing leg were also obtained. Three-dimensional spatial imaging of the tumor metabolism was performed using differential nitroxide reduction.

Effect of misonidazole and low‐oxygen treatment on mouse tumors

AbstractThe tumor cytotoxic activity of a bioreductive agent is dependent on the extent of tumor hypoxia. It is to be expected, therefore, that the tumor cytotoxicity of misonidazole will vary depending on whether it was administered to mice exposed only to an air‐breathing environment or whether it was administered either before mice were treated with 8% oxygen for 48 hr (maximal tumor levels of the drug will then coincide with an increase in tumor hypoxia) or after mice completed a 48‐hr 8% oxygen treatment (maximal tumor levels of the drug will now coincide with a reduction in the tumor hypoxic fraction). This was investigated using the 3‐methylcholanthrene‐induced rhabdomyosarcoma in BALB/c mice, the Fib/T tumor in WHT mice, and the CaNT tumor in CBA mice. The response of all three tumor types to the various treatments was determined by assessing post‐treatment tumor growth. An excision and in vitro colony‐forming assay was also used to assess Fib/T tumor response. Results indicated that only the 3‐methylcholanthrene‐induced rhabdomyosarcoma responded to misonidazole and only when the 48‐hr 8% oxygen exposure preceded drug administation. In explaining this result, it is proposed that misonidazole increases reperfusion damage that occurs when animals are returned to an air‐breathing environment following a low‐oxygen exposure. © Wiley‐Liss, Inc.